Christopher Kemp, PhD is a Full Professor in the Division of Human Biology at the Fred Hutchinson Cancer Research Center, and a Member of the Brotman Baty Institute for Precision Medicine. Dr. Kemp received a BA in Biology from Case Western Reserve University, an MS in Toxicology from Oregon State University and PhD in Experimental Oncology from the University of Wisconsin, Madison. He did postdoctoral research with Allan Balmain at the Beatson Institute for Cancer Research in Glasgow. He has been at the Fred Hutchinson Cancer Research Center for over 26 years where he has studied the genetics and biology and genetics of tumor progression. He is currently using functional genomic approaches to identify new cancer drug targets using patient derived tumor models. He is cofounder of Epigenomics, which focuses on early cancer detection, Cure First, a nonprofit dedicated to accelerating the discovery of safer and more effective treatments for cancer, SEngine Precision Medicine, a startup company that harnesses 3D organoid technology and AI for more effective treatment options and accelerated drug development, and The Society for Functional Precision Medicine, a nonprofit whose mission is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care.